erythropoietins


Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.
Related to erythropoietins: Hemopoietin, erythropoietin stimulating factor

erythropoietins

Hormones, produced mainly in the kidneys, that stimulates red blood cell production (erythropoiesis) in the bone marrow. The amount of hormone produced is based on monitoring of the blood flowing through the kidneys for oxygen concentration.
References in periodicals archive ?
Market Analysis III-25 Outlook III-25 Erythropoietin Market III-25 Leading EPO Drugs in Europe III-25 Biosimilars Market III-25 Table 50: Biosimilar Penetration in Select EU Countries (2013) III-26 Biosimilars Currently Licensed in Europe III-26 Strategic Corporate Developments III-27 Key Players III-28 B.
The first step in treatment is stopping erythropoietin as soon as PRCA is diagnosed.
Jacobs Immunological reaction against erythropoietin causing red-cell aplasia
Autoantibodies against erythropoietin in a patient with pure red cell aplasia.
A case of antierythropoietin antibodies following recombinant human erythropoietin treatment.
Table 13: World Long-term Projections for Blood Growth Factors by Type - Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) II-67
Table 15: World 10-Year Perspective for Blood Growth Factors by Type - Percentage Breakdown of Value Sales for Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart) II-69
Table 16: World Recent Past, Current & Future Analysis for Erythropoietins by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) II-70
Table 12: World 15-Year Perspective for Erythropoietins byGeographic Region - Percentage Breakdown of Value Sales forUS, Japan, Europe, and Rest of World Markets for Years 2003,2011 & 2017(includes corresponding Graph/Chart) II-71
DPI Receives Approvals for Erythropoietin in Three New Markets II-34
Post-receptor (intracellular) effects of erythropoietin
Traumatic brain injury and the potential protective effect of erythropoietin